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Abstract
Background: Children with autism have often been reported to have gastrointestinal problems that are more
frequent and more severe than in children from the general population.
Methods: Gastrointestinal flora and gastrointestinal status were assessed from stool samples of 58 children with
Autism Spectrum Disorders (ASD) and 39 healthy typical children of similar ages. Stool testing included bacterial
and yeast culture tests, lysozyme, lactoferrin, secretory IgA, elastase, digestion markers, short chain fatty acids
(SCFA’s), pH, and blood presence. Gastrointestinal symptoms were assessed with a modified six-item GI Severity
Index (6-GSI) questionnaire, and autistic symptoms were assessed with the Autism Treatment Evaluation Checklist
(ATEC).
Results: Gastrointestinal symptoms (assessed by the 6-GSI) were strongly correlated with the severity of autism
(assessed by the ATEC), (r = 0.59, p < 0.001). Children with 6-GSI scores above 3 had much higher ATEC Total
scores than those with 6-GSI-scores of 3 or lower (81.5 +/- 28 vs. 49.0 +/- 21, p = 0.00002).
Children with autism had much lower levels of total short chain fatty acids (-27%, p = 0.00002), including lower
levels of acetate, proprionate, and valerate; this difference was greater in the children with autism taking probiotics,
but also significant in those not taking probiotics. Children with autism had lower levels of species of Bifidobacter
(-43%, p = 0.002) and higher levels of species of Lactobacillus (+100%, p = 0.00002), but similar levels of other
bacteria and yeast using standard culture growth-based techniques. Lysozyme was somewhat lower in children
with autism (-27%, p = 0.04), possibly associated with probiotic usage. Other markers of digestive function were
similar in both groups.
Conclusions: The strong correlation of gastrointestinal symptoms with autism severity indicates that children with
more severe autism are likely to have more severe gastrointestinal symptoms and vice versa. It is possible that
autism symptoms are exacerbated or even partially due to the underlying gastrointestinal problems. The low level
of SCFA’s was partly associated with increased probiotic use, and probably partly due to either lower production
(less sacchrolytic fermentation by beneficial bacteria and/or lower intake of soluble fiber) and/or greater absorption
into the body (due to longer transit time and/or increased gut permeability).
Background
Individuals with Autism Spectrum Disorders (ASD)
often suffer from gastrointestinal problems [1]. The
exact percentage suffering from gastrointestinal (GI)
problems varies from study to study and depends on the
age of the study population, but there is a general
consensus that GI problems are common in autism.
Population-based studies which do not directly select or
bias their samples are the best way to determine the
incidence. In a study of 137 children with ASD, 24%
had a history of at least one gastrointestinal symptom,
with diarrhea being the most prevalent one – occurring
in 17% of individuals [2]. Similarly, a study of 172 chil-
dren with autism spectrum disorder found 22.7% were
positive for GI distress, primarily with diarrhea and con-
stipation [3]. A characterization study of 160 children
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with ASD found 59% had GI dysfunction with diarrhea
or unformed stools, constipation, bloating, and/or gas-
troesophageal reflux (GERD)[4]. A study of 150 children
(50 ASD, 50 controls, and 50 children with other devel-
opmental disabilities (DD)) found that 70% of children
with ASD presented gastrointestinal symptoms, com-
pared to 28% of typically developing children and 42%
of DD children [5]. Additionally, a study by our group
of 51 children with ASD compared to 40 typical con-
trols ages 3-15 found that 63% of children with autism
were reported to have moderate or severe chronic diar-
rhea and/or constipation, vs. 2% of the control children
[6]. In summary, these studies demonstrate that GI
symptoms are common in autism.
GI problems in children with autism may contribute
to the severity of the disorder. Abdominal pain, consti-
pation, and/or diarrhea are unpleasant and likely to pro-
duce frustration, decreased ability to concentrate on
tasks, behavior problems, and possibly aggression and
self-abuse, especially in children unable to communicate
their discomfort. These problems also result in a
decreased ability to learn toilet training, leading to
increased frustration for the child and their parents/
caregivers.
The cause of these GI problems is unclear, but it
appears to partly relate to abnormal gut flora and possi-
bly to the excessive use of oral antibiotics which can
alter gut flora. Several studies by our group and others
have reported significantly higher oral antibiotic use in
children with autism vs. typical children [6-10]. Oral
antibiotics were primarily used for treating otitis media
(ear infections), which may suggest an impaired immune
system. Commonly used oral antibiotics eliminate
almost all of the normal gut microbiota, which play an
important role in the breakdown of plant polysacchar-
ides, promoting gastrointestinal motility, maintaining
water balance, producing some vitamins, and competing
against pathogenic bacteria. Loss of normal gut flora can
result in the overgrowth of pathogenic flora, which can
in turn cause constipation and other problems.
Finegold et al. 2002 [11] studied fecal samples from 13
children with late-onset autism and 8 controls. They
used basic anaerobic culturing techniques to count and
isolate microorganisms, followed by Polymerase Chain
Reaction (PCR) targeting the 16 S rDNA to identify the
isolates cultivated. The number and type of Clostridium
and Ruminococcus species in children with autism dif-
fered from the control children. Song et al. 2004 [12]
followed up this study using quantitative real time PCR
targeting Clostridia strains in stool samples of children
with autism and found that Clostridium cluster groups I
and XI and Clostridium boltae had mean cell counts sig-
nificantly higher than those of control children. Parra-
cho et al. 2005 [13] used another culture-independent
technique, fluorescence in situ hybridization (FISH) tar-
geting Clostridium groups, and reported differences in
the gut microflora of children with ASD compared to
healthy children. In their study, levels of the Clostridium
histolyticum group of bacteria were higher in the ASD
children compared to typical children. C. histolyticum
bacteria are recognized toxin producers and may contri-
bute to gut dysfunction. Finegold et al. 2010 [14] used a
high throughput sequencing technique, i.e., pyrosequen-
cing to investigate gut bacteria in children with autism
vs. controls, and found several differences at the phylum
level, including higher levels of Bacteroidetes in the
severely autistic group, and higher levels of Firmicutes
in the control group. Additionally Desulfovibrio species
and Bacteroides vulgatus were present in higher num-
bers in autistic than controls
Treatment studies using a minimally absorbed oral
antibiotic (vancomycin) to treat abnormal gut flora
showed significant temporary improvements in behavior
for children with late-onset autism [15], but the benefits
were lost after treatment stopped. This study demon-
strated the importance of gastrointestinal flora and the
difficulty in permanently normalizing them.
Much focus has been given to the presence and abun-
dance of Clostridium groups in the intestines of autistic
children. Finegold 2008 [16] hypothesized that 1) the
relapse of some autistic kids after antibiotic treatment is
caused by the presence of Clostridium spores, 2) the
incidence of autism is related to the widespread expo-
sure to Clostridium spores, and 3) the increase of multi-
ple autism cases within a single family is also related to
contact with spores. Finegold also discussed the fact
that propionate has been shown to have severe neurolo-
gical effects in rats [17,18] and Clostridia species are
propionate producers [19]. No human studies have been
conducted to test whether the relative proportion of
propionate and/or its absolute concentration correlates
to autistic symptoms. However, studies by MacFabe et
al [17] have demonstrated that injecting propionate
directly into specific regions of rat brains in vivo can
cause significant behavior problems [17,18,20].
There have also been reports of decreased activity of
digestive enzymes in children with autism. One study by
Horvath and Perman 2002 [21] reported that 44 of 90
(49%) children with autism who underwent endoscopy
(because they had significant gastrointestinal problems)
had deficiencies in one or more disaccharidase enzymes,
especially lactase and maltase. They reported that all of
the children with low enzyme activity had loose stools
and/or gaseousness.
A recent study of children with autism and their first-
degree relatives found that 37% and 21%, respectively,
had increased intestinal permeability based on a lactu-
lose/mannitol test, compared to 5% of normal subjects.
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They also found that autistic patients on a gluten-free,
casein-free diet had significantly lower intestinal perme-
ability [22].
In summary, gastrointestinal problems are common in
children with ASD and may contribute to ASD beha-
vioral symptoms. However, more research is needed. In
this study we investigate some gut flora and biomarkers
of GI function in children with ASD compared to typi-
cal children. The gut flora investigated include both
beneficial and pathogenic bacteria that are easily cul-
tured, but the culture methods used were able to detect
only some of the bacteria present, and some anaerobic
bacteria such as clostridia were not able to be detected.
Methods
This paper reports on the study of children with autism
compared to typical children. This study was conducted
with the approval of the Human Subjects Institutional
Review Board of Arizona State University.
Participants: Participants were recruited from Arizona
with the help of the Autism Society of America -
Greater Phoenix Chapter. All parents and (where possi-
ble) children signed parent consent/child assent forms.
The control group was also recruited with the help of
the Autism Society of America - Greater Phoenix Chap-
ter, but the control group participants were not related
to children with autism.
Enrollment criteria
1) Age 2 1/2 to 18 years
2) No usage of any type of antibiotic or antifungal
medications within the last month.
3) Autism Group: diagnosis of autism, PDD/NOS, or
Asperger’s by a psychiatrist or similar professional (no
additional assessment was done in this study)
4) Control Group: In good mental and physical health:
no stomach/gut problems such as chronic diarrhea, con-
stipation, gas, heartburn, bloating, etc. No Attention
Deficit Disorders (ADD/ADHD). Unrelated to an indivi-
dual with autism (not a brother, sister, parent, aunt, or
uncle). Based on parent report (no additional assessment
was done in this study).
Participants
The characteristics of the study participants are listed in
Table 1. They were similar in age, but the control group
had a higher percentage of females, and a lower severity
of gastrointestinal problems.
Study Protocol
1) The study was explained to participants and
informed parent consent/child assent was received.
2) Parents filled out a questionnaire on their child’s
gastrointestinal status. Parents of children with autism
also filled out the Autism Treatment Evaluation Check-
list (ATEC) (Rimland and Edelson 2000) [23].
3) Stool samples were collected and sent by 2-day
express shipping to Doctor’s Data in a blinded fashion.
Severity Scales
Autism severity was assessed with the Autism Treat-
ment Evaluation Checklist (ATEC), an instrument which
was designed to provide a quantitative assessment of
autism severity. It is composed of four subscales: 1)
speech/language/communication, 2) sociability, 3) sen-
sory/cognitive awareness, and 4) health/physical beha-
vior. The sum of the scores for each subscale gives the
total ATEC score. The internal reliability of the ATEC
is very high (0.94 for the Total score), based on a split-
half reliability test on over 1,300 completed ATECs.
Gastrointestinal symptoms were assessed using a mod-
ified version of the GI Severity Index [24]. Specifically,
we included only the first six items (constipation, diar-
rhea, stool consistency, stool smell, flatulence, and
abdominal pain), but did not include “unexplained day-
time irritability”, “nighttime awakening,” or “abdominal
tenderness.” We call this shortened version the 6-GI
Severity Index (6-GSI).
Lab Methodology
All laboratory measurements were conducted by Doc-
tor’s Data (St. Charles, IL, USA - http://www.doctors-
data.com). Doctor’s Data is certified by CLIA, the
Clinical Laboratory Improvement Amendments program
operated by the US Department of Health and Human
Services which oversees approximately 200,000 labora-
tories in the US.
Table 1 Characterization of participants
Autism/
Aspergers
Control P-value
Total # participants 58 39 –
Male/Female 50/8 18/21
Age (years) 6.91 ± 3.4 7.7 ± 4.4 n.s.
% Autism/Aspergers 94.8/5.2 – –
ATEC 68.8 ± 29.5 – –
6-GSI 3.9 ± 2.5 1.3 ± 1.4 0.0000011
Probiotic Usage 33% 5%
Seafood Consumption 12% high
(> 2x/month)
33% high
(> 2x/month)
2% low
(1-2x/month)
3% low
(1-2x/month)
53% none 64% none
33% unknown
Fish Oil Consumption
(daily)
36% 0%
1The difference in 6-GSI scores is expected since controls were chosen not to
have significant GI problems, whereas children with autism were accepted
into the study regardless of their GI problems.
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Collection, Preservation & Transport
A single stool sample was collected, and then material
was added to 3 collection tubes:
1. Remel Cary Blair Transport Media Tube was used
for the transportation, preservation and examination of
stool specimens for enteric bacteria. This tube provides
a low nutrient, low oxidation-reduction potential and
high pH environment which allows for successful recov-
ery of stool pathogens and other organisms of interest.
Internal stability studies by Doctor’s Data have shown
consistent identification and recovery of organisms mea-
sured every 2 days for 14 days after collection.
2. Remel SAF Fixative Tube was used to preserve stool
and maintain the morphology of the parasites and cellu-
lar material.
3. An empty sterile tube was used for Chemistry test-
ing. Stool was frozen immediately after collection, and
sent frozen to the laboratory in an insulated container
with a frozen cold pack. All samples were verified as
frozen on arrival at Doctor’s Data.
Bacterial/Yeast Culture, ID & Susceptibility
The process of bacterial cultivation involves the use of
optimal artificial media and incubation conditions to
isolate and identify the bacterial etiologies of an infec-
tion as rapidly and as accurately as possible. For this
study we used many growth media including 5% Sheep
Blood Agar (BAP), MacConkey Agar (MAC), Columbia
Agar (CNA), Hektoen Enteric Agar (HEK), GN Broth,
Sab/Dex Gent (yeast media), and Modified Columbia
Agar.
Quantification
The quantification of culture-based methods was done
on a scale of 1-4, defined as: 1+ = Rare, 2+ = Few, 3+ =
Moderate, and 4+ = Many or Heavy growth of microor-
ganisms. The estimates of recovery are:
0 = no growth, less than 103 colony forming units/
gram of feces = 1+ growth
103 - 104 colony forming units/gram of feces = 2+
growth
105 - 106 colony forming units/gram of feces = 3+
growth
> 107 colony forming units/gram of feces = 4+ growth
Colony-forming unit (CFU or cfu) is a measure of
viable bacterial or fungal numbers. Unlike direct micro-
scopic counts where all cells, dead and living, are
counted, CFU measures viable cells.
Identification
The Vitek®2 Gram Negative (GN) identification card
was used in conjunction with the Vitek®2 system for
the automated identification of microorganisms of the
family Enterobacteriacaea. In addition, a select group of
glucose non-fermenting gram-negative bacteria, Pasteur-
ella multocida, and members of the family Vibrionaceae
can be identified.
The Vitek®2 Gram Positive (GP) identification card
was used in conjunction with the Vitek®2 system for
the automated identification of microorganisms of clini-
cally significant streptococci, staphylococci, and a
selected group of gram-positive bacilli.
The Vitek®2 Gram Negative Antimicrobial Suscept-
ibility Test (GN-AST) card was used in conjunction
with the Vitek®2 system for the automated quantitative
or qualitative susceptibility testing of isolated colonies
for most clinically significant aerobic gram-negative
bacilli. The system evaluates each organism’s growth
pattern in the presence and absence of antibiotics. The
Minimum Inhibitory Concentration (MIC) is determined
based on growth characteristics.
The Vitek®2 Yeast (YST) identification card was used
in conjunction with the Vitek®2 system for the auto-
mated identification of most significant yeasts and yeast-
like organisms.
Parasitology
Both a concentration method and a trichrome stain
were used to identify parasites. The purpose of the con-
centration method is to separate parasites from fecal
debris and to concentrate any parasites present through
sedimentation. The parasitology processing and identifi-
cation procedure is a two-step process. The concentra-
tion process is the first step, which uses centrifugation.
Ethyl acetate is used as an extractor of debris and fat
from the feces and leaves the parasites at the bottom of
the suspension. Wet mounts are examined for parasites
from the concentrated sediment using iodine as a stain
to enhance morphology.
Stained fecal films are the single most productive
means of stool examination for intestinal protozoa. The
permanent stained smear facilitates detection and identi-
fication of cysts and trophozoites and affords a perma-
nent record of the protozoa encountered. The trichrome
technique of Wheatley for fecal specimens is a modifica-
tion of Gomori’s original staining procedure for tissue.
It is a rapid, simple procedure that produces uniformly
well-stained smears of intestinal protozoa, human cells,
yeast cells and artifacts.
The parasitology test was used on the first 20 autism
samples only, which were all negative. It was then
decided to do no additional testing on other samples.
Stool Chemistry Testing
Lysozyme (muramidase) is a protein that belongs to the
group of alkaline glycosidases. The main source for fecal
lysozyme is the intestinal granulocytes. To some extent,
mononuclear cells in the bowel lumen also secrete
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lysozyme actively. Lysozyme is an enzyme with bacterio-
cidal properties. It is secreted by recruited macrophages
and monocytes at the site of inflammation. Lysozyme is
useful in the diagnosis and monitoring of Crohn’s Dis-
ease and also in bacterial, viral, allergenic, and autoim-
mune caused bowel inflammations [25,26]. An Enzyme-
Linked-Immuno-Sorbent-Assay (ELISA) was used for
the quantitative determination of lysozyme in stool,
using the Lysozyme ELISA Kit (ALPCO Diagnostics Cat.
No. 30-6900) [27].
Lactoferrin: In inflammatory diarrhea, fecal leukocytes
are found in the stool in large numbers [28]. Lactoferrin
serves as a marker for leukocytes in acute diarrhea. It is
very stable and is not degraded during infections by the
toxins of pathogens. The purpose of this test is to differ-
entiate between inflammatory bowel disease (IBD) and
non-inflammatory bowel syndrome (NIBS) [29-31]. The
measurement was performed with IBD-Scan® Kit (Tech-
Lab®Blackburg, VA) [32].
Secretory IgA (sIgA) is the major immunoglobulin in
saliva, tears, colostrum, nasal mucous, mother’s milk,
tracheobronchial and gastrointestinal secretions [33,34].
It plays a major role in preventing adherence of micro-
organisms to mucosal sites, in activating the alternative
complement pathway, and in activating inflammatory
reactions [35]. Fecal sIgA is elevated in a response of
the mucosa immune system, an imbalanced immunolo-
gical barrier on the intestinal mucosa, and in an auto-
immune disease [36]. It is decreased in children with
sIgA deficiencies. The test was performed with the
Secretory IgA ELISA Kit (ALPCO Diagnostics Cat. No.
30-8870).
Elastase: The Elastase enzyme level can be used for the
diagnosis or the exclusion of exocrine pancreatic insuffi-
ciency, which may be associated with chronic pancreati-
tis, cystic fibrosis, carcinoma of the pancreas, Diabetes
mellitus Type 1, Shwachman-Diamond syndrome and
other etiologies of pancreatic insufficiency. The test was
performed with the Elastase ELISA BIOSERV Kit (Joli
Medical Products Inc.).
Short chain fatty acids (SCFA) are the end products
of anaerobic microbial fermentation of dietary fiber
[37]. Levels thus reflect the concentration of intestinal
flora as well as soluble fiber in the diet [38,39]. The
SCFA distribution reflects the relative proportions of
the beneficial SCFA (n-butyrate, propionate and acet-
ate), thus providing an indirect measure of balance
among the anaerobic organisms in the colon. These
beneficial SCFA are crucial to the health of the intes-
tine, serving as sources of fuel for the cells and the
rest of the body. Decreased levels may reflect insuffi-
cient normal colonic flora, a diet low in soluble fiber,
or prolonged intestinal transit time [39]. Abnormal
level of short chain fatty acids in stool can indicate
malabsorption and are used as metabolic markers.
Levels of butyrate and Total SCFA’s in mg/mL are
important for assessing overall SCFA production, and
are reflective of beneficial flora levels and/or fiber
intake [40].
The “volatile” fatty acids in fecal samples were
extracted into an HCl solution and quantified using a
flame ionization detector (FID) following separation by
gas chromatography(GC) [41,42]. The SCFAs that were
measured include acetate, proprionate, butyrate, and
valerate. Results were verified to be accurate and precise
using quality control.
Statistical Analysis
Several types of statistical analyses were carried out,
depending on the research question being addressed. In
comparing levels between groups (such as children with
autism vs. typical children), 2-sided unpaired (indepen-
dent sample) t-tests were used. The unpaired t-tests
were either done assuming equal variance (if F-test
results had p-values greater than 0.05), or assuming
unequal variance (if F-test p-values were less than 0.05).
For individual comparisons a p-value of 0.05 or lower
was assumed significant. However, when multiple com-
parisons were considered, then a lower p-value was con-
sidered significant based on a Bonferroni analysis - this
is defined at the beginning of each section of the results.
Pearson correlation coefficients were obtained to deter-
mine the strengths of linear relationships among the
variables involved in the analyses.
In some cases the data was not normally distributed.
Those cases included lysozyme, lactoferrin, E. coli, and
Enterococcus. For those cases, a non-parametric Wilcox
analysis was used to compare the autism group and the
typical group.
In addressing questions about the relationships
between autism severity and GI severity, correlation ana-
lyses were performed.
Results
Beneficial Bacteria
Four types of beneficial bacteria were investigated,
including bifidobacteria, Lactobacillus spp. (all strains,
since all are beneficial), E. Coli, and Enteroccus - see
Table 2. The children with autism had much lower
levels of Bifidobacterium (-45%, p = 0.002), slightly
lower levels of Enterococcus (-16%, p = 0.05 per Wilcox),
and much higher levels of Lactobacillus (+100%, p =
0.00003).
Dysbiotic Bacteria
Table 3 lists the dysbiotic bacteria, which were observed
during aerobic culture growth. Since these bacteria were
only observed rarely, the table lists how many
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individuals had measurable levels of these bacteria, and
the average levels of the bacteria. There were no signifi-
cant differences between the children with autism and
the typical children.
Commensal Bacteria
Some bacteria are not believed to be especially benefi-
cial or detrimental, and we term those commensal bac-
teria, and list the results for them in Table 4. Since
these bacteria were only observed rarely, the table lists
how many individuals had measurable levels of these
bacteria, as well as the average level. The only possibly
significant differences were that the autism group was
more likely to have Bacillus spp (21% vs. 2.6%, p =
0.05) and less likely to have Klebsiella oxytoca (1.7% vs.
12.8%, p = 0.04).
Yeast
The presence of yeast was determined by both culture
and by microscopic observation. Yeast was only rarely
observed by culture in the autism or typical groups, and
the difference between the two groups was not signifi-
cant, as shown in Table 5. Yeast was more commonly
observed microscopically, but again the difference
between the two groups was not significant.
Digestion
Elastase, a digestive enzyme, was measured and found to
be similar in both the autism and typical groups, shown
in Table 6. The presence of fat, muscle fibers, vegetable
fibers, and monosaccharides were measured in both
groups, and again no significant differences were found.
Inflammation
Possible markers of inflammation, including lysozyme,
lactoferrin, white blood cells, and mucus, were investi-
gated and shown in Table 7. The autism group had a
lower level of lysozyme (-27%, p = 0.03 by Wilcox analy-
sis), but no other significant differences.
Secretory IgA
Levels of secretory IgA were measured, and no signifi-
cant difference between the two groups was observed as
shown on Table 8. Secretory IgA was highly correlated
Table 2 Beneficial bacteria from stool analysis
Autism/
Aspergers
Control P-value % Difference
Bifidobacterium 1.6 ± 1.9 2.8 ± 1.8 0.002 -44%
E.coli 2.8 ± 1.7 2.4 ± 1.6 n.s.
Lactobacillus 2.6 ± 1.4 1.3 ± 1.4 0.00002 +100%
Enterococcus 0.81 ± 1.4 0.97 ± 1.2 0.05 W -16%
W - The data for the enterococcus was not normally distributed, so it was
analyzed with a non-parametric Wilcox analysis.
Bacteriology culture values ranged from 0 to 4.
Table 3 Dysbiotic bacteria found in stool analysis
Autism/Aspergers Control P-value
Citrobacter youngae 3.4%
(0.14 ± 0.7)
5.1%
(0.18 ± 0.8)
n.s.
Citrobacter braakii None detected 2.6%
(0.08 ± 0.5)
n.s.
Proteus mirabills 3.4%
(0.14 ± 0.7)
2.6%
(0.08 ± 0.5)
n.s.
Salmonella 1.7%
(0.07 ± 0.5)
None detected n.s.
Citrobacter freundii 1.7%
(0.05 ± 0.4)
2.6%
(0.18 ± 0.8)
n.s.
Values indicate percentage of participants with detectable (> 0) bacteria with
average numerical values and standard deviation in parenthesis.
Table 4 Commensal bacteria found in stool analysis
Autism/
Aspergers
Control P-
value
%
Difference
Bacillus spp. 21%
(0.280 ± 64)
2.6%
(0.05 ± 0.3)
0.05 +438%
Klebsiella
pneumonia
12.1%
(0.29 ± 0.94)
17.9%
(0.23 ± 0.5)
n.s.
Klebsiella oxytoca* 1.7%
(0.03 ± 0.26)
12.8%
(0.31 ± 0.9)
0.04 -89%
Pseudomonas
aeruginosa*
10.3%
(0.17 ± 0.6)
12.8%
(0.21 ± 0.6)
n.s.
Haemolytic E.coli 17.2%
(0.64 ± 1.4)
20.5%
(0.67 ± 1.4)
n.s.
Gamma strep 29.3%
(0.98 ± 1.6)
43.6%
(0.79 ± 1.2)
n.s.
Alpha Haemolytic
strep
13.8%
(0.40 ± 1.1)
46.2%
(0.74 ± 1.0)
n.s.
Staphylococcus
aureus
13.8%
(0.24 ± 0.7)
20.5%
(0.28 ± 0.6)
n.s.
Enterobacter
cloacae
8.6%
(0.09 ± 0.3)
12.8%
(0.33 ± 1.0
0.07 -33%
*Indicates bacteria were either listed as commensal or dysbiotic depending on
concentration.
The table indicates the percentage of participants with detectable (> 0).
bacteria and in parenthesis average values and standard deviation. Numerical
values of bacteriology culture ranged from 0-4.
Table 5 Cultured and microscopic yeast
Autism/Aspergers Control P-value
Candida albicans 15.6%
(0.24 ± 0.7)
10.3%
(0.13 ± 0.4)
n.s.
Other yeast 12.1%
(0.12 ± 0.3)
2.6%
(0.05 ± 0.3)
n.s.
Dysbiotic yeast 6.9%
(0.14 ± 0.8)
None detected n.s.
Yeast (microscopic) 70.7%
(1.45 ± 1.4)
84.7%
(1.87 ± 1.4)
n.s.
The table indicates the percentage of participants with detectable (> 0)
bacteria and in parenthesis average values and standard deviation.
Numerical values of bacteriology culture ranged from 0-4. Variations in
cultured and microscopic concentrations are typical due to the non-uniform
distribution of yeast in the stool.
Adams et al. BMC Gastroenterology 2011, 11:22
http://www.biomedcentral.com/1471-230X/11/22
Page 6 of 13
with lysozyme for the autism group (R = 0.69, p <
0.001), and moderately correlated for the controls (R =
0.35, p < 0.01).
Short Chain Fatty Acids
The presence of several short chain fatty acids (SCFA),
including acetate, proprionate, butyrate, and valerate
were measured. The total amount of SCFA was signifi-
cantly lower in children with autism (-27%, p =
0.00003). Similarly, the levels of acetate, proprionate,
and valerate were also lower in the autism group, as
shown in Table 9. The lower level of SCFA’s appears to
be partly due to probiotic usage (see Effect of Probiotics
section below). The low level of SCFA’s is also partly
due to lower sacchrolytic fermentation by beneficial bac-
teria, lower intake of soluble fiber, prolonged transit
time due to constipation, and/or possibly increased
absorption by the gut due to increased permeability.
However, from this study we cannot determine among
those possibilities.
Intestinal Health
The presence of RBC or occult blood was very rare in
both groups, and not significantly different between the
two groups. The fecal pH, a reflection of colonic pH,
was very similar in both groups, although the autism
group had a somewhat larger standard deviation, as
listed in Table 10. (F-test for equal value p-value =
0.0004).
Gender Differences
Gender differences were investigated in the typical
group for all of the measurements, and there were no
statistically significant differences between males and
females, expect for a possibly significant higher level of
yeast in the females (p = 0.04). For the autism group,
there were too few females to justify comparing the
males vs. females.
Effect of Probiotics
The autism group was split into two groups, A-Probiotic
(those that used any type of probiotic daily) and those
that did not use any probiotics, A-No-Probiotic. The
only significant differences (p < 0.01) were that, com-
pared to the A-No Probiotic group, the A-Probiotic
group had a lower level of total SCFA’s and each indivi-
dual SCFA - see Table 9 and Figure 1. Probiotics did
not have a significant effect on most of the beneficial
bacteria, except for a marginally higher level of the level
of lactobacillus in the A-Probiotic group compared to
the A-No-Probiotic group (+30%, p = 0.08).
The A-Probiotic group had a lower level of lysozyme
than did the A-No-Probiotic group, but the difference
was not significant (277 +/- 231 vs. 371 +/- 302, n.s.).
(see Lysozyme section). A t-test comparison of lysozyme
in the autism groups with the Control group found a
significantly lower level in the A-Probiotic group (31%
lower, p = 0.03), but no significant difference for the A-
No-Probiotic group (-11%, n.s.).
For the control group, only 5% used a probiotic, so
they were not analyzed separately.
Effect of Seafood and Fish Oil Consumption
The autism group was split into three groups based on
consumption of seafood and fish oil (see Table 11):
A- Fish - Consumption of seafood more than 2x/
month - (57% also consumed fish oil daily)
A- Fish Oil - No consumption of seafood; consumes
fish oil supplement daily
A-No Fish - No consumption of seafood or fish oil
The typical group was divided similarly, but none of
the typicals were consuming fish oil regularly.
A t-test comparison of those groups found only two
biomarkers which differed between the groups with
Table 6 Digestion/Absorption Markers
Autism/Aspergers Control P-value
Elastase
(μg/mL)
487.0 ± 38.3 481.5 ± 61.1 n.s.
Fat Stain 0.17 ± 0.6 0.21 ± 0.6 n.s.
Muscle Fibers 0.19 ± 0.4 0.33 ± 0.5 n.s.
Vegetable Fibers 1.24 ± 0.6 1.28 ± 0.5 n.s.
Carbohydrates 0.17 +/- 0.68 None detected n.s.
Fat stain, muscle fibers, and vegetable fibers were rated 0-4 with 0 = none, 1
= rare, 2 = few, 3 = moderate, 4 = many. Carbohydrates were listed as either
negative or positive with a positive value indicating carbohydrate
malabsorption from the presence of reducing substances in the stool sample.
Table 7 Summary of inflammatory markers found in the
stool analysis
Autism/
Aspergers
Control P-
value
%
Difference
Lysozyme
(ng/ml)
334 ± 282 464 ± 337 0.04 -28%
Lactoferrin
(μg/mL
7.6 ± 18 4.4 ± 8.7 n.s.
WBC None detected None
detected
n.s.
Mucus 1.7% Positive
(0.02 ± 0.13)
None
detected
n.s.
Mucus was indicated as either negative or positive.
Table 8 Secretory IgA (sIgA) in stool (mg/dL)
Autism/Aspergers Control P-value
Secretory IgA 166 ± 183 165 ± 249 n.s.
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p < 0.01, namely lactobacillus and pH. Regarding Lac-
tobacillus, the A-Fish Oil and the A-No Fish had simi-
lar levels, but the A-Fish had dramatically lower levels
than the other two groups. Regarding pH, the A-Fish
Oil group had slightly higher pH values than the other
two groups.
The control group was split into only two groups, C-
Fish and C-No Fish, because none of the controls con-
sumed fish oil (see Table 11). There were no significant
differences between the two groups.
Kruskall-Wallis Analysis on Lactobacillus
Since exploratory data analysis with t-tests found that
levels of lactobacillus were associated with both fish
consumption and probiotic usage, a Kruskall-Wallis
rank sum test (which treat the data as the ranked values
that they are) was conducted. For the autistic group,
Lactobacillus levels were very significantly related to
levels of fish consumption (p = 0.0008) and adding
other variables (ie, fish oil consumption or probiotics)
did not add to the significance of the relationship. No
relationships were found for the control group.
Effect of Gut Symptoms in Autism Group
The autism group had significantly greater gut symp-
toms than the control group in part because the control
group was chosen to be “in good health: no stomach/
gut problems.” To investigate the effect of gastrointest-
inal problems on the results, the autism group was split
into two groups: Low-GI-Problems (defined as 6-GSI of
3 or less) and High-GI-Problems (defined as 6-GSI
score above 3). The two groups were compared for all
the biomarkers reported above, and there were no sig-
nificant differences (p < 0.01) in any biomarkers.
However, the ATEC scores of the two groups were
very different, and this is reported in Table 12 and dis-
played in Figure 2. The total ATEC score was 66%
higher in the High-GI-Problem group (p = 0.00002),
and the four subscales were also higher (+40% to
+103%, p < 0.01).
Correlations with Gut Symptoms and Autism Severity
For the autism group, the 6-GSI was found to strongly
and very significantly correlate with the total ATEC (r =
0.60, p < 0.001); see Figure 3. Due to this strong correla-
tion, correlations with the ATEC subscales were also
determined and are listed in Table 13.
Correlations of each biomarker of gut status with the
6-GSI and the total ATEC scores were investigated.
(However, comparisons with individual bacteria and
yeast were not done, since in most samples they were
not detected, and the large number of the comparisons
made the required per-comparison p-value very low).
For the 6-GSI there was a small correlation with carbo-
hydrates (R = 0.27, p = 0.04). For the total ATEC, there
was a small correlation with lysozyme (R = 0.29, p =
0.03). However, since multiple correlation analyses were
conducted, the cut-off for significance (p = 0.05) should
be divided by the number of tests. So, these correlations
are at most only possibly significant, and a larger study
would be needed to assess this possible weak
correlation.
Table 9 Summary of short chain fatty acids (SCFA’s) in stool
Acetate Butyrate Propionate Valerate Total SCFA’s
Autism/Asperger’s 3.5 +/- 1.4 1.63 +/- 1.2 1.28 +/- 0.5 0.22 +/- 0.1 6.7 +/- 2.8
A-Probiotics
(n = 19)
2.94 +/- 1.4 1.00 +/- 0.7 1.02 +/- 0.37 0.17 +/- 0.10 5.13 +/- 2.2
A-No-Probiotics
(n = 38)
3.84 +/- 1.3 1.95 +/- 1.25 1.43 +/- 0.54 0.24 +/- 0.12 7.5 +/- 2.8
Controls 5.2 +/- 1.6 2.00 +/- 0.9 1.64 +/- 0.6 0.36 +/- 0.3 9.2 +/- 2.6
Ttest Comparisons
A-Probiotics vs. A-No Probiotics P = 0.02 P = 0.003 P = 0.004 P = 0.02 P = 0.002
A-Probiotics vs. Controls P = 0.000002 P = 0.0001 P = 0.00007 P = 0.02 P = 0.0000002
A-No-Probiotics vs. Controls P = 0.00009 n.s. P = 0.09 P = 0.05 P = 0.006
All autism vs. Controls P = 0.0000003
(-32%)
P = 0.005
(-18%)
P = 0.002
(-22%)
P = 0.005
(-39%)
P = 0.00002
(-27%)
Each fatty acid is expressed in units of mg/mL.
Table 10 Intestinal Health Markers
Autism/Aspergers Control P-value
RBC 5.2%
(0.10 ± 0.55)
7.7%
(0.08 ± 0.27)
n.s.
pH 6.46 ± 0.51 6.49 ± 0.29 n.s.
Occult Blood 3.4% 7.7% n.s.
Red blood cells (RBC) reference range listed numerically with 0 = none, 1 =
rare, 2 = few, 3 = moderate and 4 = many. Occult blood listed as percentage
of cases with positive findings of occult blood.
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Discussion
The very strong correlation of the 6-GSI with the ATEC
and its subscales indicates that there is a very strong
association of gastrointestinal symptoms and autistic
symptoms. Of course, association does not mean causa-
tion, but the effectiveness of oral, non-absorbable anti-
biotics in temporarily reducing autistic symptoms [15]
does suggest that the relationship may be causal; ie, we
hypothesize that gastrointestinal problems may signifi-
cantly contribute to autistic symptoms in some children.
The lower levels of SCFA’s were extremely significant.
The A-Probiotic group had much lower levels than the
controls (-44%, p = 0.0000002), but the A-No-Probiotic
group also had lower levels that the controls (-19%, p =
0.006). This suggests that there are either lower
amounts of beneficial bacteria which produce SCFA’s, a
lower intake of soluble fiber, a longer transit time, and/
or increased absorption due to increased gut permeabil-
ity. The latter possible explanation is very intriguing
because of work by MacFabe et al. 2007 [17], which
demonstrates that SCFA’s can induce autistic-like symp-
toms when injected into rats. In other words, if lower
levels of SCFA’s in the stool are due to increased
absorption, then this presumably would lead to higher
level of SCFA’s entering the bloodstream, and hence
would exacerbate autistic symptoms. If however, lower
levels of SCFA’s in the stool are due to lower amounts
of SCFA-producing bacteria or low fiber intake, there
may not be higher SCFA levels in the bloodstream. So,
our results suggest that measurements of SCFA’s in
blood and/or urine samples are warranted.
Lysozyme is an important part of the immune system,
and protects the gut from pathogenic bacteria by enzy-
matic attack of their cell walls. It is secreted by recruited
macrophages, monocytes, and granulocytes at the site of
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Figure 1 Comparison of SCFA’s for the Autism-Probiotic group, the Autism-No-Probiotic group, and the controls. Note that the Valerate
data is magnified 10x so that it is visible on the chart. The stars indicate the degree of significance of the result of a t-test comparison of the
level of SCFA’s in the autism subgroup (Probiotic or No-Probiotic) vs. the controls - * p < 0.05, ** p < 0.01, *** p < 0.001.
Table 11 Consumption of Fish and Fish Oil
Lactobacillus pH
A-Fish (n = 7) 0.71 +/- 0.95 6.20 +/- 0.25
A-Fish Oil (n = 15) 3.00 +/- 1.26 6.84 +/- 0.52
A-No Fish (n = 34) 2.90 +/- 1.37 6.44 +/- 0.50
C-Fish (n = 13) 0.85 +/- 1.1 6.47 +/- 0.24
C- No Fish (n = 22) 1.60 +/- 1.5 6.52 +/- 0.31
T-Test Comparisons
t-test: A-Fish vs. A-Fish Oil p = 0.0009 p = 0.009
t-test: A-Fish vs. A-No Fish p = 0.0007 n.s.
t-test: A-Fish Oil vs. A-No Fish n.s. p = 0.05
t-test: C-Fish vs. C-No Fish n.s. n.s.
Autism Subgroups and Control Subgroups compared. Only biomarkers with p
< 0.01 are listed.
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inflammation. Infants fed formula without lysozyme
have three times the rate of diarrheal disease [43]. In
this study, lysozyme levels were lower in children with
autism (-28%, p = 0.04); this difference was significant
for the A-Probiotic group, but not for the A-No-Probio-
tic group. We hypothesize that probiotics provide some
limited defense against pathogenic bacteria, and thus
decrease the need for the immune system to excrete
lysozyme.
The unusually broad distribution of pH in the autistic
group suggests that there is a general disregulation of
pH, which could affect digestion and bacteria. pH was
negatively correlated with lysozyme (R = -0.34, p =
0.01), suggesting that higher pH is associated with lower
levels of lysozyme and vice versa. Also, pH was even
more strongly negatively correlated with total SCFA (R
= - 0.44, p < 0.001), presumably because SCFA’s contri-
bute to colonic pH.
The lower amounts of bifidobacteria (-44%, p = 0.002)
in children with autism is consistent with a pyrosequen-
cing study [14] that also found lower levels of bifidobac-
teria (-37%, p = 0.05) in children with autism, and
suggests that supplementation with bifidobacteria is
worth investigating. The high levels of lactobacillus in
the autism group was partly associated with decreased
rate of seafood consumption.
It was interesting that dysbiotic bacteria were present
at similar (low) levels in both groups. However, it
Table 12 ATEC scores for the Autism-Low-GI-Problem group (6-GSI score of 3 or lower) and for the Autism-High-GI-
Problem group (GSI-6 score above 3)
Autism-Low-GI-Problem Group
(n = 22)
Autism-High-GI-Problem Group
(n = 34)
% difference p-value from ttest
6-GSI score 1.4 +/- 0.8 5.4 +/- 1.7 +295%
ATEC-total 49.0 +/- 21 81.5 +/-27.6 +66% 0.00002
ATEC Subscales
Speech/Language/Communication 6.7 +/- 4.4 13.7 +/- 8.0 +103% 0.0005
Sociability 11.5 +/- 5.3 17.6 +/- 7.6 +53% 0.002
Sensory/Cognitive Awareness 12.6 +/- 7.0 17.6 +/- 6.8 +40% 0.01
Health/Physical Behavior 18.7 +/- 9.1 32.6 +/- 12.0 +74% 0.00003
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should be noted that many bacteria such as clostridia
would not be detected by the culture-based methods
used in the present study, except for Clostridium difficile
if present at high levels. Feingold’s pyrosequencing study
[14] estimated that typical children normally have about
500-600 species of bacteria in their gut and estimated
that children with autism have about twice that, so it is
important to remember that we are only able to culture
a small fraction of the species present.
The finding that yeast levels were similar in both the
autistic and control group is interesting, as there has
been a great deal of speculation that yeast infections are
a major problem in autism. Our data indicates that
yeast is present at normal levels in the stool of this
group of children with autism. A study by Horvath and
Perman [21] reported that 43% of children with autism
undergoing endoscopies had a positive fungal culture
for yeast in their duodenal juice, vs. 23% of age-matched
controls with other gastrointestinal problems requiring
endoscopies. Since their study involved children with
severe enough symptoms to warrant endoscopies, the
greater symptom severity may explain some of the dif-
ference with our study. Since the survey by the Autism
Research Institute of over 25,000 parents’ reports that
parents find antifungals to be one of the most effective
medications for improving behavior [44], our findings
are puzzling. It is possible that children with autism are
more sensitive to even a normal level of yeast. Also, it is
possible that antifungals have other effects, such as
reducing inflammation.
Study Limitations
1) The diagnosis of an autism spectrum disorder was
made by a qualified medical professional prior to enroll-
ment in the study, but there was no additional verifica-
tion. Similarly, for the neurotypical children, no
additional verification was made beyond the parental
report.
2) One limitation of this study is that the children
with autism had more gastrointestinal problems, lower
fish consumption, more fish oil consumption, and more
probiotic usage. This greatly complicated the study ana-
lysis, but provided interesting insights into these effects.
The results for these subgroups should be interpreted
cautiously, if at all, due to the smaller size of the sub-
groups and potential confounding of fish and fish oil
consumption results. Larger, more carefully designed
studies are needed to investigate these issues properly.
Conclusion
The strong correlation of the 6-GSI and the ATEC (r =
0.59) strongly suggests that gastrointestinal problems are
associated with autism severity. The autism group with
low GI problems had much lower scores on the ATEC
and each of its four subscales compared to the the aut-
ism group with high GI problems.
6-GSI vs. total ATEC 
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Figure 3 6-Item Gastrointestinal Severity Index (6-GSI) vs. total ATEC score.
Table 13 Correlations between total ATEC and subset
divisions and total GI Severity
Autism/Aspergers P-value
Total ATEC r= 0.60 < 0.001
I. Speech/Language/Communication r = 0.47 < 0.001
II. Sociability r = 0.50 < 0.001
III. Sensory/Cognitive Awareness r = 0.34 0.01
IV. Health/Physical/Behavior r = 0.62 < 0.001
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The autism group had a low level of SCFA’s, partly
associated with probiotic usage, and probably partly due
to either lower sacchrolytic fermentation by beneficial
bacteria, due to their relative absence, lower intake of
soluble fiber, longer transit time, and/or increased gut
permeability.
The lower levels of Bifidobacterium and higher levels
of Lactobacillus suggests an imbalance in beneficial bac-
teria. Increased levels of Lactobacillus were strongly
associated with decreased seafood consumption is the
autism group (p = 0.0008).
Lysozyme were lower in the autism group compared
to controls, and the lower levels of lyszoymes were asso-
ciated with probiotic usage; it is possible that probiotics
decrease the need for lysozyme to be excreted to defend
against pathogenic bacteria.
Acknowledgements
First and foremost, we thank the many autism families and their friends who
volunteered as participants in this research study. We thank the Autism
Research Institute for financial support of this study. We thank the Autism
Society of Greater Phoenix for assistance with advertising this study. We
thank Doctor’s Data for providing testing for this study. We thank James
Alling for help with study logistics. We thank Jon Pangborn and Sharon
McDonough Means for very helpful comments on the manuscript.
Author details
1School for Engineering of Matter, Transport, and Energy, Arizona State
University, Tempe, AZ, USA. 2Doctor’s Data, St. Charles, IL, USA. 3Department
of Mathematics, Whittier College, Whittier, CA, USA.
Authors’ contributions
JBA was the principal investigator, oversaw the study design, conducted
most of the data analysis, and wrote most of the paper. LJJ assisted with
participant recruitment, data analysis, and paper preparation. LDP assisted
with participant recruitment and data analysis. DQ oversaw the testing at
Doctors Data, led the writing of the laboratory methodology sections, and
helped with interpreting the results. RAR assisted with statistical analysis and
editing the paper. All authors read and approved the final version of the
paper.
Competing interests
The authors declare that they have no competing interests.
Received: 28 September 2010 Accepted: 16 March 2011
Published: 16 March 2011
References
1. Buie T, Fuchs GJ, Furuta GT, Kooros K, Levy J, Lewis JD, Wershil BK,
Winter H: Recommendations for evaluation and treatment of common
gastrointestinal problems in children with ASDs. Pediatrics 2010,
125(Suppl 1):S19-29.
2. Molloy CA, Manning-Courtney P: Prevalence of chronic gastrointestinal
symptoms in children with autism and autistic spectrum disorders.
Autism 2003, 7(2):165-171.
3. Nikolov Roumen N, Bearss Karen E, Jelle Lettinga, Craig Erickson,
Maria Rodowski, Aman Michael G, McCracken James T, McDougle
Christopher J, Elaine Tierney, Benedetto Vitiello, Eugene LArnold,
Bhavik Shah, Posey David J, Louise Ritz, Lawrence Scahill: Gastrointestinal
Symptoms in a Sample of Children with Pervasive Developmental
Disorders. J Autism Dev Disord 2009, 39:405-413.
4. Xue Ming, Michael Brimacombe, Janti Chaaban, Barbie Zimmerman-Bier,
Wagner George C: Autism Spectrum Disorders: Concurrent Clinical
Disorders. J Child Neurol 2008, 23(1):6-13.
5. Valicenti-McDermott M, McVicar K, Rapin I, Wershil BK, Cohen H, Shinnar S:
Frequency of gastrointestinal symptoms in children with autistic
spectrum disorders and association with family history of autoimmune
disease. J Dev Behav Pediatr 2006, 27(2 Suppl):S128-36.
6. Adams JB, Holloway CE, George F, Quig D: Analyses of Toxic Metals and
Essential Minerals in the Hair of Arizona Children with Autism and their
mothers. Biol Tr El Res 2006, 110:193-209.
7. Adams JB, Romdalvik J, Ramanujam VMS, Legator MS: Mercury, Lead, and
Zinc in Baby Teeth of Children with Autism vs. Controls. J Toxicol Environ
Health 2007, 70(12):1046-51.
8. Adams JB, Romdalvik J, Levine KE, Hu L-W: Mercury in First-Cut Baby Hair
of Children with Autism vs. Typically-Developing Children. Toxicological
and Environmental Chemistry 2008, 90(4):739-753.
9. Konstantareas MM, Homatidis S: Ear infections in autistic and normal-
children. Journal of Autism and Developmental Disorders 1987,
17(4):585-594.
10. Niehus R, Lord C: Early medical history of children with autism spectrum
disorders. Journal of Developmental and Behavioral Pediatrics 2006, 27(2):
S120-S127.
11. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M,
Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P,
Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H,
Haake DA, Manning P, Kaul A: Gastrointestinal microflora studies in late-
onset autism. Clinical Infectious Diseases 2002, 35:S6-S16.
12. Song YL, CX Liu, Finegold SA: Real-time PCR quantitation of clostridia in
Feces of autistic children. Applied and Environmental Microbiology 2004,
70(11):6459-6465.
13. Parracho HM, Bingham MO, Gibson GR, McCartney AL: Differences
between the gut microflora of children with autistic spectrum disorders
and that of healthy children. Journal of Medical Microbiology 2005,
54(10):987-991.
14. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD,
Youn E, Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR,
Green JA: Pyrosequencing study of fecal microflora of autistic and
control children. Anaerobe 2010, 16(4):444-53.
15. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML,
Nelson MN, Wexler HM: Short-term benefit from oral vancomycin
treatment of regressive-onset autism. Journal of Child Neurology 2000,
15(7):429-435.
16. Finegold SM: Therapy and epidemiology of autism-clostridial spores as
key elements. Medical Hypotheses 2008, 70(3):508-511.
17. MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F,
Taylor AR, Kavaliers M, Ossenkopp KP: Neurobiological effects of
intraventricular propionic acid in rats: Possible role of short chain fatty
acids on the pathogenesis and characteristics of autism spectrum
disorders. Behav Brain Res 2007, 176(1):149-69.
18. Shultz SR, MacFabe DF, Ossenkopp KP, Scratch S, Whelan J, Taylor R,
Cain DP: Intracerebroventricular injection of propionic acid, an enteric
bacterial metabolic end-product, impairs social behavior in the rat:
Implications for an animal model of autism. Neuropharmacology 2008,
54(6):901-911.
19. Elsden SR, Hilton MG: Volatile acid production from threonine, valine,
leucine and isoleucine by clostridia. Arch Microbiol 1978, 117(2):165-72.
20. Shultz SR, Macfabe DF, Martin S, Jackson J, Taylor R, Boon F, Ossenkopp KP,
Cain DP: Intracerebroventricular injections of the enteric bacterial
metabolic product propionic acid impair cognition and sensorimotor
ability in the Long-Evans rat: further development of a rodent model of
autism. Behav Brain Res 2009, 200(1):33-41.
21. Horvath K, Perman JA: Autism and gastrointestinal symptoms. Curr
Gastroenterol Rep 2002, 4(3):251-8.
22. de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P,
Carteni M, De Rosa M, Francavilla R, Riegler G, Militerni R, Bravaccio C:
Alterations of the Intestinal Barrier in Patients With Autism Spectrum
Disorders and in Their First-degree Relatives. J Pediatr Gastroenterol Nutr ,
http://www.ncbi.nlm.nih.gov/pubmed/20683204.
23. Rimland B, Edelson S: Autism Treatment Evaluation Checklist: Statistical
Analyses. Autism Research Institute, San Diego, CA; 2000.
24. Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J,
Ostrem JA: Oral human immunoglobulin for children with autism and
gastrointestinal dysfunction: a prospective, open-label study. Journal
Autism Developmental Disorders 2006, 36(8):1053-64.
Adams et al. BMC Gastroenterology 2011, 11:22
http://www.biomedcentral.com/1471-230X/11/22
Page 12 of 13
25. Reifenstein RW, Gray SJ: The Effect of Adrenocorticotropic Hormone upon
the Fecal Lysozyme Titer in Ulcerative Colitis. Gastroenterology 1951,
19(3):547-557.
26. Van Der Sluys Veer A, Brouwer J, Biemond I, Bohbouth GE, Verspaget HW,
Lamers CBHW: Fecal Lysozyme in Assessment of Disease Activity in
Inflammatory Bowel Disease. Digestive Diseases and Sciences 1998,
43(3):590-595.
27. Dugad L: Performance Verification of Lysozyme ELISA Test Kit
Verification 105. Doctor’s Data, Inc. Saint Charles, Illinois; 2007.
28. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AAM, Cooper WH, Lee AG:
Measurement of Fecal Lactoferrin as a Marker of Fecal Leukocytes.
Journal of Clinical Microbiology 1992, 30:1238-1242.
29. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M,
Hanauer SB: Fecal Lactoferrin is a Sensitive and Specific Marker in
Identifying Intestinal Inflammation. The American Journal of
Gastroenterology 2003, 98(6):1309-1314.
30. Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K,
Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K: Lactoferrin in Whole
Gut Lavage Fluid as a Marker for Disease Activity in Inflammatory Bowel
Disease: Comparison with Other Neutrophil-Derived Proteins. The
American Journal of Gastroenterology 2002, 97(2):360-369.
31. Fine KD, Ogunji F, George J, Niehaus BA, Guerrant RL: Utility of a Rapid
Fecal Latex Agglutination Test Detecting the Neutrophil Protein,
Lactoferrin, for Diagnosing Inflammatory Causes of Chronic Diarrhea. The
American Journal of Gastroenterology 1998, 93(8):1300-1305.
32. Dugad L, Wu Z: PerformanceVerification of Lactoferrin ELISA Test Kit of
Fecal Verification 104. Doctor’s Data Inc, Saint Charles, Illinois; 2007.
33. Kudoh K, Shimizu J, Ishiyama A, Wada M, Takita T, Kanke Y, Innami S:
Secretion and Excretion of Immunoglobulin A to Cecum and Feces
Differ with Type of Indigestible Saccharides. J Nutr Sci Vitaminol 1999,
45:173-181.
34. Nishio O, Sakae K, Ishihara Y, Isomura S, Inouye S: Adenovirus Infection
and Specific Secretory IgA Responses in the Intestine of Infants. Microbiol
Immunol 1992, 36(6):623-631.
35. Stals F, Walther F, Bruggeman CA: Faecal and Pharyngeal Shedding of
Rotavirus and Rotavirus IgA in Children with Diarrhea. Journal of Medical
Virology 1984, 14:333-339.
36. Scerpella EG, Gould SS, Mathewson JJ, DuPont HL: Methods for Detection
of an Intestinal Secretory Immunoglobulin A Response to Candida spp.
and Their Preliminary Application in Human Immunodeficiency Virus-
Infected Patients with Chronic Diarrhea. Clinical and Diagnostic Laboratory
Immunology 1995, 2(2):246-248.
37. Zarling EJ, Ruchim MA: Protein Origin of the Volatile Fatty Acids Iso-
Butyrate and Iso-Valerate in Human Stool. J Lab Clin Med 1987,
109:566-70.
38. Araki Y, Andoh A, Fujiyama Y, Itoh A, Bamba T: In vitro Alterations in Fecal
Short Chain Fatty Acids and Organic Anions Induced by the Destruction
of Intestinal Microflora under Hypotonic and Aerobic Conditions. Int J
Mol Med 2002, 9(6):627-631.
39. Topping DL, Clifton PM: Short Chain Fatty Acids and Human Colonic
Function: Roles of Resistant Starch and Nonstarch Polysaccharides.
Physiol Reviews 2001, 81(3):1031-1064.
40. Garner Catherine E, Stephen Smith, de Lacy Costello Ben, Paul White,
Robert Spencer, Probert Chris SJ, Ratcliffe Norman M: Volatile organic
compounds from feces and their potential for diagnosis of
gastrointestinal disease. FASEB J 2007, 21:1675-1688.
41. Collin DP, McCormick PG: Determination of Short Chain Fatty Acids in
Stool Ultrafiltrate and Urine. Clin Chem 1974, 20(9):1173-1180.
42. Collin DP, McCormick PG, Schmitt MG Jr: Quantitative Gas-
Chromatographic Determination of Short Chain Fatty Acids in Aqueous
Samples. Clin Chem 1974, 20(9):1235-1237.
43. Lönnerdal B: Nutritional and physiologic significance of human milk
proteins. Am J Clin Nutr 2003, 77(6):1537S-1543S.
44. Edelson S: Parent Ratings of Behavioral Effects of Biomedical
Interventions. Autism Research Institute, Publication 34, San Diego, CA;
2010.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/11/22/prepub
doi:10.1186/1471-230X-11-22
Cite this article as: Adams et al.: Gastrointestinal flora and
gastrointestinal status in children with autism–comparisons to typical
children and correlation with autism severity. BMC Gastroenterology 2011
11:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Adams et al. BMC Gastroenterology 2011, 11:22
http://www.biomedcentral.com/1471-230X/11/22
Page 13 of 13
